-
Product Insights
Galectin 3 – Drugs In Development, 2023
Global Markets Direct’s Galectin 3 provides in depth analysis on Galectin 3 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Galectin 3 targeted therapeutics development and features...
-
Product Insights
Galectin 1 – Drugs In Development, 2023
Global Markets Direct’s Galectin 1 provides in depth analysis on Galectin 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Galectin 1 targeted therapeutics development and features...
-
Product Insights
NewNet Present Value Model: Galectin Therapeutics Inc’s Belapectin
Empower your strategies with our Net Present Value Model: Galectin Therapeutics Inc's Belapectin report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYT-200 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYT-200 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYT-200 in Myelodysplastic Syndrome Drug Details: LYT-200 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYT-200 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYT-200 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYT-200 in Refractory Acute Myeloid Leukemia Drug Details: LYT-200 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYT-200 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYT-200 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYT-200 in Relapsed Acute Myeloid Leukemia Drug Details: LYT-200 is...
-
Product Insights
Portal Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Portal Hypertension - Drugs In Development, 2023’, provides an overview of the Portal Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Arrhythmias – Drugs In Development, 2023
Global Markets Direct’s, ‘Arrhythmias - Drugs In Development, 2023’, provides an overview of the Arrhythmias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selvigaltin in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Selvigaltin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Selvigaltin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Selvigaltin is...